HOIST is developing anti-cancer products with novel mechanism-of-action utilizing the MA-T® system. Further, we are pursuing epitranscriptomics drug discovery via a novel target, ALKBH. In addition, we run a drug discovery support business for our clients creating patient derived cells (PDC) / patient derived xenografts (PDX). In pharmaceutical development, HOIST aims to utilize partnerships with pharmaceutical companies (via licensing-out, joint drug discovery etc.). In the drug discovery support business, we tailor PDC/PDX solutions to individual needs of our clients, and contribute to higher success rate of product development.
We provide a system that analyzes medical images using AI and outputs musculoskeletal data.
Tellme's original business was operating hair salons. Over years of observing changes in their clientele, and as a service for customers who could no longer visit the salon due to illness or aging, the company developed a technology to assess the risk of glycation (a measure of aging) through hair analysis. This technology is currently being promoted as a diabetes screening technology. After being featured at the World Expo, it gained significant attention from overseas countries and institutions for its ability to assess risk without the need for blood sampling. In Japan, the technology is also seen as contributing to behavioral change among the segment of the population indifferent to their own health (kenko mukanshinsō) within local municipalities. Tellme is now pursuing the commercialization of this service as a means of optimizing social security costs.
Elcyo develops innovative autofocal glasses that automatically adjust focus with proprietary lens technology. Leveraging Fresnel Liquid Crystal Lens Technology, Elcyo has made it possible to create glasses that maintain focus at any distance, addressing a wide range of vision challenges across healthcare, entertainment, and beyond.
With more than 30 years of experience in developing tactile and sensory measurement technologies, Jun Wada founded Hapquitous in 2023 upon turning 60. Guided by the mission of “bringing the potential of sensation and perception to anyone, anywhere,” Hapquitous developed Pain Compass®, a novel device based on the Thermal Grill Illusion (TGI). The system provides a three-minute assessment that objectively evaluates stress-related hypersensitivity in the brain and visualizes presenteeism—conditions that typically remain hidden in the workplace. Hapquitous offers an integrated solution that connects measurement → intervention (acupuncture, exercise, psychological support) → follow-up assessment, enabling early detection and improvement of employee well-being. Hapquitous is currently conducting collaborative research with ten institutions, including Kyoto Tachibana University, Kio University, and the University of Tokyo School of Medicine.
